The reporting standards of randomised controlled trials in leading medical journals between 2019 and 2020: a systematic review

Mairead McErlean¹ · Jack Samways² · Peter J. Godolphin³ · Yang Chen⁴

Received: 25 August 2021 / Accepted: 9 February 2022 / Published online: 3 March 2022
© The Author(s), corrected publication 2022

Abstract
Randomised controlled trials (RCTs) are the gold standard study design used to evaluate the safety and effectiveness of healthcare interventions. The reporting quality of RCTs is of fundamental importance for readers to appropriately analyse and understand the design and results of studies which are often labelled as practice changing papers. The aim of this article is to assess the reporting standards of a representative sample of randomised controlled trials (RCTs) published between 2019 and 2020 in four of the highest impact factor general medical journals. A systematic review of the electronic database Medline was conducted. Eligible RCTs included those published in the New England Journal of Medicine, Lancet, Journal of the American Medical Association, and British Medical Journal between January 1, 2019, and June 9, 2020. The study protocol was registered on medRxiv (https://doi.org/10.1101/2020.07.06.20147074). Of a total eligible sample of 497 studies, 50 full-text RCTs were reviewed against the CONSORT 2010 statement and relevant extensions where necessary. The mean adherence to the CONSORT checklist was 90% (SD 9%). There were specific items on the CONSORT checklist which had recurring suboptimal adherence, including in title (item 1a, 70% adherence), randomisation (items 9 and 10, 56% and 30% adherence) and outcomes and estimation (item 17b, 62% adherence). Amongst a sample of RCTs published in four of the highest impact factor general medical journals, there was good overall adherence to the CONSORT 2010 statement. However, there remains significant room for improvement in areas such as description of allocation concealment and implementation of randomisation.

Keywords CONSORT · Randomised controlled trial (RCT) · Reporting guidelines

Introduction
Randomised controlled trials (RCTs) are the gold standard study design used to evaluate the safety and effectiveness of healthcare interventions [1]. When published in academic journals, many years of work, often at significant financial cost, may be summarised in fewer than 5000 words. It is therefore imperative that the reporting quality of an RCT is transparent and clear, allowing readers to appropriately analyse and understand the study design and results that may change clinical practice. In an attempt to improve trial reporting, the Consolidated Standards of Reporting Trials (CONSORT) statement was developed in 1996 [2]. Since its inception, there have been significant updates in 2001 and 2010 [3, 4]. The current iteration consists of a 25-item checklist for correct trial reporting.

Previous studies have shown poor reporting standards in RCTs, particularly in areas concerning trial methodology [5–8]. More recently, a 2016 systematic review of reporting
standards of RCTs within Cardiology reinforced this point—adherence to CONSORT items was only 63.8% (SD 18.1%) [9].

This study aims to assess the reporting standard of a representative sample of RCTs published between 2019 and 2020 four of the highest impact general medical journals [9]. Given the dramatic changes that the COVID-19 pandemic has brought to academia, including greater use of pre-prints and scrutiny of the data veracity of studies, the importance of robust reporting of RCTs is more salient that ever.

Methods

The protocol for this systematic review was registered before data extraction, as a preprint on the medRxiv database https://doi.org/10.1101/2020.07.06.20147074, following an initial attempt to register on PROSPERO. This was declined on the grounds of not fulfilling the scope of PROSPERO, despite similar works being registered [10]. This manuscript has been prepared according to the updated 2020 guidelines issued by the PRISMA group [11]. A checklist is available in the Supplemental Appendices along with a list of protocol deviations and justifications.

Eligibility criteria

Studies were eligible for inclusion if they (1) described the primary results of a randomised trial; (2) were published in the New England Journal of Medicine, the Lancet, the Journal of the American Medical Association or the British Medical Journal articles; and (3) were English language publications.

Study identification

We performed a comprehensive search of the terms ‘New England Journal of Medicine’, ‘Lancet’, ‘Journal of the American Medical Association’ and ‘British Medical Journal’ on MEDLINE only, given that these target journals are all MEDLINE indexed. To identify RCTs for inclusion, the Cochrane Highly Sensitive Search Strategies for identifying randomised trials filter was used [12]. A time filter was applied to obtain results from January 1, 2019, to June 9, 2020 (the date of the search execution).

Study selection and data extraction

After removal of duplicates and clearly irrelevant records, two independent reviewers (MM, JS) screened the titles and abstracts of the search results. The full texts of the remaining results were individually assessed by both reviewers for inclusion with arbitration by a third author if necessary (YC).

Data from eligible studies was extracted from study reports independently by three reviewers (MM, JS and PG) including the general characteristics of the RCTs.

Adherence to reporting standards

A random sample of 50 papers was selected to score against the CONSORT checklist using a random number list generated by one reviewer (PG). The software package Stata SE version 16.0 (StataCorp, College Station, TX, USA) was used to generate the random number list. Papers were scored independently by three authors (MM, JS and PG) against the 25-item 2010 CONSORT statement.

Each item was given an equal weighting—12 items were divided into A and B parts giving a total of 37 points scored per paper. Each item was subdivided as outlined in the CONSORT statement [4]. Any differences in scores were resolved through consensus. The CONSORT Extension statement was used for RCTs that included designs other than a parallel 2-arm comparison [13–15]. Two papers from each scorer were selected at random and audited independently by the corresponding author (YC). If auditing revealed significant discrepancies, a re-evaluation of the original scoring was triggered.

Risk of bias and data synthesis

We did not conduct a risk of bias assessment nor a quantitative synthesis.

Results

Identified and eligible studies

A total of 1,413 records were retrieved by electronic searches, last updated on June 9, 2020 (see Fig. 1). After removal of duplicates, 568 full texts were assessed of which 71 were excluded. A final list of 50 papers was chosen at random for full analysis against the CONSORT statement.

Of the 50 RCTs selected for full CONSORT scoring, their general characteristics are summarised in Table 1. Their representativeness compared to the 497 eligible RCTs is described, along with a full table of characteristics of all eligible studies, in the supplementary materials. The overall adherence to CONSORT items was high—across all the studies, the average adherence was 90% (SD 9%), and only 4 RCTs (8%) scored less than 75% adherence to relevant CONSORT 2010 items (Table 2). Compliance was variable between different CONSORT 2010 items. This is shown in Table 3 and was poorest for items relating to title, item 1a
(35/50, 70%); allocation concealment, item 9 (28/50, 56%); implementation, item 10 (15/50, 30%); and outcomes and estimation, item 17b (21/34, 62%).

**Discussion**

Our study has three principal findings. Firstly, the general reporting standard of RCTs in high impact medical journals in 2019–2020 is strong. Nine papers had either full or all but one item fully adherent to the CONSORT 2010 guidance. Second, there were common and important areas where performance was suboptimal—namely in allocation concealment and implementation of randomisation. Third, there was a significant number of cluster and factorial study designs—14% of the studies analysed were scored using their relevant CONSORT extension document.

Our findings demonstrate a marked improvement from previous systematic reviews [7, 8] which admittedly included RCTs from a more heterogeneous group of journals. More broadly, whilst the adoption and use of reporting guidelines are prominent in RCTs, there remains work to be done across other study designs and areas of medicine, notably highlighted in a recent paper examining high impact rehabilitation journals [16]. Other groups have considered additional extensions to CONSORT—in particular a more detailed description of the interventions used in RCTs [17].
Table 2  List of selected studies and their adherence to the CONSORT 2010 Statement or relevant extension and the % adherence when assessed against relevant items

| Author               | Journal | RCT design                                      | Number of adhered CONSORT items | Number of relevant CONSORT items | Overall CONSORT adherence |
|----------------------|---------|------------------------------------------------|---------------------------------|---------------------------------|---------------------------|
| Al Batran et al      | Lancet  | Parallel group 2-arm                            | 32                              | 33                              | 97%                       |
| Bernitz et al        | Lancet  | Cluster randomised parallel group 2-arm          | 30                              | 33                              | 91%                       |
| Burtness et al       | Lancet  | Parallel group 3-arm                            | 30                              | 34                              | 88%                       |
| Campbell et al       | JAMA    | Parallel group 2-arm                            | 30                              | 33                              | 91%                       |
| Claassens et al      | NEJM    | Parallel group 2-arm                            | 30                              | 35                              | 86%                       |
| Cohen et al          | Lancet  | Parallel group 2-arm                            | 34                              | 34                              | 100%                      |
| Diener et al         | NEJM    | Parallel group 2-arm                            | 30                              | 34                              | 88%                       |
| Fisher et al         | JAMA    | Parallel group 2-arm                            | 32                              | 34                              | 94%                       |
| Futier et al         | JAMA    | Parallel group 2-arm                            | 32                              | 35                              | 91%                       |
| Gimbel et al         | Lancet  | Parallel group 2-arm                            | 32                              | 34                              | 94%                       |
| Gonzalez-Martin et al| NEJM    | Parallel group 2-arm                            | 31                              | 37                              | 84%                       |
| Hajek et al          | NEJM    | Parallel group 2-arm                            | 31                              | 33                              | 94%                       |
| Hanley et al         | Lancet  | Parallel group 2-arm                            | 31                              | 34                              | 91%                       |
| Hausenloy et al      | Lancet  | Parallel group 2-arm                            | 32                              | 34                              | 94%                       |
| Havlir et al         | NEJM    | Cluster randomised parallel group 2-arm          | 23                              | 34                              | 68%                       |
| Huang et al          | NEJM    | Parallel group 2-arm                            | 29                              | 33                              | 88%                       |
| Issa et al           | JAMA    | Parallel group 2-arm                            | 34                              | 34                              | 100%                      |
| Keene et al          | BMJ     | Parallel group 2-arm                            | 32                              | 33                              | 97%                       |
| Khorana et al        | NEJM    | Parallel group 2-arm                            | 26                              | 32                              | 81%                       |
| Kim et al            | JAMA    | Parallel group 2-arm                            | 30                              | 32                              | 94%                       |
| Kortekangas et al    | BMJ     | Noninferiority Parallel group 3-arm             | 32                              | 32                              | 100%                      |
| Kroon et al          | Lancet  | Parallel group 2-arm                            | 34                              | 34                              | 100%                      |
| Lemkes et al         | NEJM    | Parallel group 2-arm                            | 23                              | 30                              | 77%                       |
| Liu-Ambrose et al    | JAMA    | Parallel group 2-arm                            | 33                              | 33                              | 100%                      |
| Makkar et al         | NEJM    | Parallel group 2-arm                            | 22                              | 32                              | 69%                       |
| Manson et al         | NEJM    | 2 × 2 Factorial                                 | 19                              | 33                              | 58%                       |
| Masa et al           | Lancet  | Parallel group 2-arm                            | 30                              | 33                              | 91%                       |
| McCann et al         | Lancet  | Parallel group 2-arm                            | 33                              | 33                              | 100%                      |
| Mehanna et al        | Lancet  | Parallel group 2-arm                            | 29                              | 30                              | 97%                       |
| Milstone et al       | JAMA    | Parallel group 2-arm                            | 34                              | 35                              | 97%                       |
| Nagel et al          | NEJM    | Noninferiority Parallel group 2-arm             | 25                              | 29                              | 86%                       |
| Parsons et al        | JAMA    | Parallel group 2-arm                            | 28                              | 30                              | 93%                       |
| Pittock et al        | NEJM    | Parallel group 2-arm                            | 32                              | 36                              | 89%                       |
| Rosenbergstock et al | JAMA    | Parallel group 2-arm                            | 29                              | 33                              | 88%                       |
| Sands et al          | NEJM    | Parallel group 2-arm                            | 25                              | 34                              | 74%                       |
| Schupke et al        | NEJM    | Parallel group 2-arm                            | 30                              | 33                              | 91%                       |
| Shehabi et al        | NEJM    | Parallel group 2-arm                            | 29                              | 33                              | 88%                       |
| Sheppard et al       | JAMA    | Parallel group 2-arm                            | 32                              | 33                              | 97%                       |
| Skjerven et al       | Lancet  | 2 × 2 factorial, cluster randomised             | 32                              | 33                              | 97%                       |
| Spahn et al          | Lancet  | Parallel group 2-arm                            | 29                              | 33                              | 88%                       |
| Staedke et al        | Lancet  | Cluster randomised 2-arm                        | 32                              | 34                              | 94%                       |
| Tang et al           | BMJ     | Parallel group 2-arm                            | 33                              | 33                              | 100%                      |
| Taylor et al         | Lancet  | Parallel group 3-arm                            | 32                              | 33                              | 97%                       |
| van Kempen et al     | NEJM    | Parallel group 2-arm                            | 28                              | 33                              | 85%                       |
| von Dach et al       | JAMA    | Parallel 3-arm                                  | 31                              | 33                              | 94%                       |
| Walsh et al          | NEJM    | 2 × 2 factorial                                 | 30                              | 34                              | 88%                       |
| Wolf et al           | JAMA    | Parallel group 2-arm                            | 29                              | 33                              | 88%                       |
How this becomes blended together with other initiatives to achieve a consistently high standard of RCT reporting remains a challenge for future work.

In current RCT reporting published within journals that represent the pinnacle of academia, areas of concern remain. The reporting of important steps in the randomisation

Table 2  (continued)

| Author | Journal | RCT design | Number of adhered CONSORT items | Number of relevant CONSORT items | Overall CONSORT adherence |
|--------|---------|------------|---------------------------------|---------------------------------|---------------------------|
| Writing Committee for the PROBESE Collaborative Group | JAMA | ×2 Parallel group 2-arm | 33 | 35 | 94% |
| Young et al | JAMA | Cluster crossover | 31 | 34 | 91% |
| Younossi et al | Lancet | ×2 Parallel group 2-arm | 32 | 34 | 94% |

Table 3  CONSORT 2010 adherence by individual item. For items 3b, 6b, 7b, 11a, 11b, 12b, 17b and 18, these were not applicable for many of the included sample for analysis

| Section/topic | Item no | Checklist item | Adherence |
|---------------|---------|----------------|-----------|
| Title and abstract | 1a | Identification as a randomised trial in the title | 35/50 (70%) |
| | 1b | Structured summary of trial design, methods, results and conclusions (for specific guidance see CONSORT for abstracts) | 50/50 (100%) |
| Background and objectives | 2a | Scientific background and explanation of rationale | 47/50 (94%) |
| | 2b | Specific objectives or hypotheses | 44/50 (88%) |
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio | 48/50 (96%) |
| | 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 7/8 (88%) |
| Participants | 4a | Eligibility criteria for participants | 49/50 (98%) |
| | 4b | Settings and locations where the data were collected | 44/50 (88%) |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 50/50 (100%) |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 48/50 (96%) |
| | 6b | Any changes to trial outcomes after the trial commenced, with reasons | 6/6 (100%) |
| Sample size | 7a | How sample size was determined | 45/50 (90%) |
| | 7b | When applicable, explanation of any interim analyses and stopping guidelines | 21/21 (100%) |
| Randomisation: | | | |
| Sequence generation | 8a | Method used to generate the random allocation sequence | 43/50 (86%) |
| | 8b | Type of randomisation; details of any restriction (such as blocking and block size) | 47/50 (94%) |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 28/50 (56%) |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants and who assigned participants to interventions | 15/50 (30%) |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | 41/43 (95%) |
| | 11b | If relevant, description of the similarity of interventions | 8/11 (73%) |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | 49/50 (98%) |
| | 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | 43/45 (96%) |
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment and were analysed for the primary outcome | 46/50 (92%) |
| | 13b | For each group, losses and exclusions after randomisation, together with reasons | 47/50 (94%) |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | 48/50 (96%) |
| | 14b | Why the trial ended or was stopped | 48/50 (96%) |
process such as allocation concealment and implementation are areas of weakness. Whilst editors are confined by limited journal space, there may be a role for 100–200 words of protected text to allow for adequate description of the main strength of an RCT design—the component of randomisation. As an editorial described at the time of release of CONSORT, if ‘the whole of medicine depends on the transparent reporting of clinical trials’ [1], then the cost of an extra couple of paragraphs or a clearly signposted and structured appendix to find detailed descriptions of the randomisation process should be prioritised, given that robust methodology is held in as high regard as the result of the trial itself.

The reporting of some basic CONSORT items remains consistently poor across time; for instance, omission of the word ‘randomised’ in the title was noted in nearly half of CONSORT abstracts of the same medical journals in a 2012 analysis [18]. There is no clear explanation for why this remains the case though the definition of quality of reporting is not simply limited to CONSORT checklist adherence. Indeed one could argue that for journals such as the NEJM, article titles do not require explicit conformity given the entry criteria for publishing original research on their platform necessitates robust methodological design.

Lastly, the word count limits imposed by the journals vary considerably—ranging from 2700 words in the NEJM to an unrestricted upper end in the BMJ (see supplementary materials). We noted that whilst many of the sections are interchangeable across the different journal platforms, there were advantages to the more liberal constraints of the BMJ, particularly with regard to mandatory reporting of patient and public involvement, and thus focusing readers’ attention in thinking about the value of the study that they are reading with reference to the views and input of patients who may benefit from such results. Whilst a counter-argument to restricted space is that there is almost always co-publication of supplementary material which can contain helpful additional information to the reader, what remains unknown is the number of times such material is ever downloaded and read.

### Limitations

Our findings must be considered in the light of several limitations. First, there is inherent subjectivity to the way that adherence to CONSORT items are judged. Although we used independent reviewers and adjudication to reach consensus, there may nevertheless remain small variation in findings if results were to be replicated. Second, we chose only 50 papers to be scored—this was to balance against feasibility and comprehensiveness, and our sample size is similar to existing reviews which have examined reporting standards [7, 8]. Random sampling represented the most robust method to select papers from our initial eligible list, though this may not capture the extent to which CONSORT scores may vary depending on different study designs or subject areas. If a larger sample was assessed, then possible associations could be uncovered. Of note, there is also a significant difference between the

| Section/topic | Item no | Checklist item                                                                 | Adherence |
|---------------|---------|---------------------------------------------------------------------------------|-----------|
| Baseline data | 15      | A table showing baseline demographic and clinical characteristics for each group| 47/50 (94%) |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | 48/50 (96%) |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group and the estimated effect size and its precision (such as 95% confidence interval) | 47/50 (94%) |
| Ancillary analyses | 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | 21/34 (62%) |
| Harms | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | 46/46 (100%) |
| Limitations | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | 47/50 (94%) |
| Generalisability | 20 | Generalisability (external validity, applicability) of the trial findings | 44/50 (88%) |
| Interpretation | 21 | Interpretation consistent with results, balancing benefits and harms and considering other relevant evidence | 50/50 (100%) |
| Registration | 22 | Registration number and name of trial registry | 50/50 (100%) |
| Protocol | 23 | Where the full trial protocol can be accessed, if available | 50/50 (100%) |
| Funding | 24 | Sources of funding and other support (such as supply of drugs), role of funders | 50/50 (100%) |
number of articles contributed by each journal—although this is broadly representative of the full 497 studies identified, the relative contribution of each journal is unequal and should temper overall conclusions.

Lastly, the choice of restriction to four of the highest impact general medical journals has substantially limited the number of RCTs that were possible to be analysed, of which many have a wide readership within specialty subject areas—for example, the European Heart Journal. Our contention is that by focusing on the journals with the largest academic circulation and readership, the assumption is that the reporting standards of the published RCTs are likely to be amongst the best within the research community. RCTs in other journals will likely require just as much if not more focus on ensuring that their reporting quality remains as close to what is advocated by the CONSORT group as possible—a standard that has garnered almost universal support amongst quality medical journals.

Conclusion

Amongst RCTs published between 2019 and 2020 within four of the highest impact factor general medical journals, there is strong adherence to the CONSORT 2010 statement. Specific components still have room for improvement, with allocation concealment and implementation of the randomisation process representing areas for particular focus.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s11845-022-02955-6.

Author contribution MM and YC conceived the study idea. All authors contributed to the study protocol. YC created the search strategy, MM, PG and JS collected the data. YC wrote the first draft of the article. All authors contributed to critical revision of the article for important intellectual content and approved the final version. YC is the guarantor.

Availability of data See supplement.

Declarations

Ethics approval Not applicable.

Conflict of interest The authors declare no competing interests.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Rennie D (2006) CONSORT revised—improving the reporting of randomized trials. JAMA 2001(285):7
2. Begg C, Cho M, Eastwood S et al (1996) Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 276(8):637–639
3. Moher D, Schulz KF, Altman DG, CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 134(8):657–62
4. Moher D, Hopewell S, Schulz KF et al (2010) CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340:c669
5. Chan HL, Liu K (2012) Reporting in randomized trials published in International Journal of Cardiology in 2011 compared to the recommendations made in CONSORT 2010. Int J Cardiol 160:208–210
6. Chan AW, Altman DG (2005) Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 365:1159–1162
7. Camm CF, Chen Y, Sunderland N et al (2013) An assessment of the reporting quality of randomised controlled trials relating to anti-arrhythmic agents (2002–2011). Int J Cardiol 15. pii: S0167–5273(12)01649-X. https://doi.org/10.1016/j.ijcard.2012.12.020. PMID 23298560
8. Zheng SL, Chan FT, Maclean E et al (2016) Reporting trends of randomised controlled trials in heart failure with preserved ejection fraction: a systematic review. Open Heart 3:e000449. https://doi.org/10.1136/openhrt-2016-000449
9. Clarivate (2022) Journal Citation Reports. Clarivate (Online) 2022. Available at: https://jcr.clarivate.com/jcr/browse-category-list. Accessed 6 Feb 2022
10. PROSPERO International prospective register of systematic reviews. A systematic review of reporting standards of anaesthetic interventions in randomised controlled trials. PROSPERO 2019 CRD42019141670 (Online). Available at: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=141670. Accessed 26 Nov 2020
11. Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71
12. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration
13. Campbell MK, Piaggio G, Elbourne DR et al (2012) Consort 2010 statement: extension to cluster randomised trials. BMJ 345:e5661
14. Piaggio G, Elbourne DR, Pocock SJ et al (2012) Reporting of noninferiority and equivalence randomised trials. Extension of the CONSORT 2010 statement. JAMA 308(24):2594–2604
15. Dimairo M, Pallmann P, Wason J et al (2020) The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ 369:m1115
16. Innocenti T, Salvioni S, Giagio S et al (2020) Declaration of use and appropriate use of reporting guidelines in high impact rehabilitation journals is limited: a meta-research study. J Clin Epidemiol S0895–4356(20):31179–31183
17. Palmer W, Okonya O, Jellison S et al (2020) Intervention reporting of clinical trials published in high-impact cardiology journals: effect of the TIDieR checklist and guide BMJ Evidence-Based Medicine Published Online First: 05 March 2020

18. Ghimire S, Kyung E, Kang W, Kim E (2012) Assessment of adherence to the CONSORT statement for quality of reports on randomized controlled trial abstracts from four high-impact general medical journals. Trials 13:77. Published 2012 Jun 7. https://doi.org/10.1186/1745-6215-13-77

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Authors and Affiliations

Mairead McErlean1 · Jack Samways2 · Peter J. Godolphin3 · Yang Chen4

1 UCLPartners, London, UK
2 Cardiology Department, London North West University Healthcare NHS Trust, London, UK
3 MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London, London, UK
4 Institute of Health Informatics, University College London, 222 Euston Road, London NW1 2DA, UK

Yang Chen
yang.a.chen@ucl.ac.uk